secwatch.observer — SEC 8-K summary
======================================

Issuer:     KalVista Pharmaceuticals, Inc. (KALV)
CIK:        0001348911
Form:       8-K
Filed at:   2021-12-09T23:59:59+00:00
Accession:  0000950170-21-005122
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KalVista reports Q2 net loss $19.7M; advances HAE oral candidates KVD900 and KVD824
--------------------------------------------------------------------------------

- Net loss of $19.7M ($0.80 per share) for quarter ended Oct 31, 2021 vs $10.4M ($0.58) year ago.
- Cash, equivalents and marketable securities $209.8M as of Oct 31, 2021; funded into early 2024.
- Preparing to initiate Phase 3 trial for KVD900 (on-demand HAE) in Q1 2022; FDA confirmed trial design.
- Phase 2 KOMPLETE trial for KVD824 (prophylactic HAE) enrolling patients; regulatory approvals in 12 of 13 countries.
- R&D expenses increased to $17.5M from $9.1M due to preclinical, Phase 2 and Phase 3 preparation costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348911/000095017021005122/0000950170-21-005122-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348911/000095017021005122/kalv-20211209.htm
  HTML page:      https://secwatch.observer/filing/0000950170-21-005122

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer